DiaMedica TherapeuticsDMAC
DMAC
About: DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
Employees: 28
0
Funds holding %
of 7,431 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
700% more call options, than puts
Call options by funds: $8K | Put options by funds: $1K
350% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 4
18% more capital invested
Capital invested by funds: $28.5M [Q1] → $33.5M (+$5.02M) [Q2]
2.49% more ownership
Funds ownership: 17.53% [Q1] → 20.03% (+2.49%) [Q2]
0% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 21
2% less funds holding
Funds holding: 57 [Q1] → 56 (-1) [Q2]
100% less funds holding in top 10
Funds holding in top 10: 1 [Q1] → 0 (-1) [Q2]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$11
83%
upside
Avg. target
$12.33
106%
upside
High target
$14
133%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Matthew Caufield | 100%upside $12 | Buy Reiterated | 15 Aug 2025 |
Craig-Hallum Chase Knickerbocker | 83%upside $11 | Buy Maintained | 18 Jul 2025 |
Lake Street Thomas Flaten | 133%upside $14 | Buy Maintained | 18 Jul 2025 |
Financial journalist opinion
Based on 7 articles about DMAC published over the past 30 days
Positive
Zacks Investment Research
1 week ago
Does DiaMedica Therapeutics (DMAC) Have the Potential to Rally 114.06% as Wall Street Analysts Expect?
The mean of analysts' price targets for DiaMedica Therapeutics (DMAC) points to an 114.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Positive
Seeking Alpha
1 week ago
DiaMedica: Interim Results Brings Study Expansions For DM199 In Preeclampsia
Positive interim phase 1a data for DM199 in preeclampsia establishes proof-of-concept and supports expansion to phase 1b and fetal growth restriction studies. DM199's mechanism targets key factors in preeclampsia, offering a potential best-in-class, disease-modifying therapy in a large, underserved market. Strong cash position of $60.1 million extends runway into 2H 2027, supporting ongoing and expanded clinical development.
Neutral
Seeking Alpha
1 week ago
DiaMedica Therapeutics Inc. (DMAC) Q2 2025 Earnings Call Transcript
DiaMedica Therapeutics Inc. (NASDAQ:DMAC ) Q2 2025 Earnings Conference Call August 13, 2025 8:00 AM ET Company Participants Dietrich John Pauls - President, CEO & Director Julie Krop - Chief Medical Officer Scott Kellen - CFO & Corporate Secretary Conference Call Participants Chase Richard Knickerbocker - Craig-Hallum Capital Group LLC, Research Division Thomas Flaten - Lake Street Capital Markets, LLC, Research Division Operator Good morning, ladies and gentlemen, and welcome to the DiaMedica Therapeutics Q2 2025 Earnings Conference Call. An audio recording of this webcast will be available shortly after the call today on DiaMedica's website at www.diamedica.com in the Investor Relations section.
Neutral
Business Wire
1 week ago
DiaMedica Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today provided a business update and reported financial results for the second quarter ended June 30, 2025. Management will host a conference call Wednesday, August 13, 2025, at 8:00 AM Eastern Time / 7:00 AM Central Time to discuss its business update and second quarter 2.
Neutral
Business Wire
2 weeks ago
DiaMedica Therapeutics Appoints Julie Krop, MD, as Chief Medical Officer
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced the appointment of Julie Krop, MD, as Chief Medical Officer (CMO), effective immediately. Dr. Krop will succeed Dr. Lorianne Masuoka, who has resigned from her position as CMO for personal reasons. “We are pleased to welcome Dr. Krop to our executive leader.
Neutral
Business Wire
2 weeks ago
DiaMedica Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Business Update August 13, 2025
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia and acute ischemic stroke, announced today that its second quarter 2025 financial results will be released after the markets close on Tuesday, August 12th. DiaMedica will host a live conference call on Wednesday, August 13th at 8:00 AM Eastern Time / 7:00 AM Central Time to provide a business update and discuss financial res.
Neutral
24/7 Wall Street
3 weeks ago
These 4 Stocks Are Seeing Huge Insider Buying
Insider buying has been slow this past month, as buy windows close as the new earnings-reporting season gets underway.
Neutral
Business Wire
1 month ago
DiaMedica Therapeutics Announces Closing of $30.1 Million Private Placement
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced the closing of its previously announced $30.1 million private placement of common shares to accredited investors. The Company sold approximately 8.6 million common shares at a purchase price of $3.50 per share. After deducting estimated offering expenses, t.
Neutral
Business Wire
1 month ago
DiaMedica Therapeutics Raises $30 Million in Private Placement to Accelerate Industry Leading Preeclampsia and Fetal Growth Restriction Pipeline
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced definitive agreements for a $30.1 million private placement of common shares led by current investors. No placement agent was engaged for this transaction. Pursuant to the terms of the securities purchase agreements, the Company will issue a total of 8,606,.
Neutral
Business Wire
1 month ago
DiaMedica Therapeutics Reports Positive Interim Phase 2 Preeclampsia Results: Statistically Significant Reductions in Blood Pressure and No Placental Transfer
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company, today announced positive interim results from Part 1a of the Phase 2 study of DM199 for the treatment of preeclampsia. The study achieved pre-specified safety and efficacy endpoints for the Part 1a dose escalation phase, reinforcing the therapeutic potential of DM199. DM199, rinvecalinase alfa, is a recombinant form of the KLK1 protein expected to influence blood pressure regula.
Charts implemented using Lightweight Charts™